The changing view of high-grade serous ovarian cancer

Cancer Research

Volumn 72, Issue 11, 2012, Pages 2701-2704

  Berns, Els M J J ^a   Bowtell, David D ^b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; DOUBLE STRANDED DNA; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; RAD50 PROTEIN; RAD51 PROTEIN; TRANSCRIPTION FACTOR PAX8;

CANCER GENETICS; CLINICAL TRIAL (TOPIC); COPY NUMBER VARIATION; DNA DAMAGE; DNA REPAIR; DRUG TARGETING; GENE AMPLIFICATION; GENE EXPRESSION; GENE INACTIVATION; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SURVIVAL RATE;

CYSTADENOCARCINOMA, SEROUS; DNA DAMAGE; FEMALE; GENE DOSAGE; GENES, BRCA1; GENES, BRCA2; HUMANS; OVARIAN NEOPLASMS;

EID: 84861860715     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3911     Document Type: Review

References (40)

1. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25.
2. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35. (Pubitemid 46092026)
3. Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010;29: 1103-13.
4. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363:1532-43.
5. Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 2011;117:554-62.
6. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009;16: 267-82.
7. Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008;5:e232.
8. Schwartz DR, Wu R, Kardia SL, Levin AM, Huang CC, Shedden KA, et al. Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 2003;63:2913-22. (Pubitemid 36667164)
9. Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002;62:4722-9.
10. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat 2003;21: 285-91. (Pubitemid 36292970)
11. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010;221:49-56.
12. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 2011;108:18032-7.
13. The Cancer Genome Atlas Research Network. Integrated genomic analysis of ovarian carcinoma. Nature 2011;474:609-15.
14. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DY, et al. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 2007;13:4731-9. (Pubitemid 47294779)
15. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010;10:803-8.
16. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306:1557-65.
17. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852-61.
18. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002;94:990-1000. (Pubitemid 34814728)
19. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-9.
20. Mukhopadhyay A, Curtin N, Plummer R, Edmondson RJ. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. BJOG 2011;118:429-32.
21. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Australian Ovarian Cancer Study Group. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008;14:5198-208.
22. Helland A, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, et al.Australian Ovarian Cancer Study Group. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS ONE 2011;6: e18064.
23. Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, et al. (2010) Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer. PLoS ONE 2010;5: e11408. doi:10.1371/journal.pone. 0011408
24. Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M, Gorringe KL, et al.Australian Ovarian Cancer Study Group. Amplicondependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS ONE 2010;5:e15498.
25. Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A 2011;108:12372-7.
26. Mittag J, Winterhager E, Bauer K, Grümmer R. Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy. Endocrinology 2007;148:719-25. (Pubitemid 46143173)
27. Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 2011;35:816-26.
28. Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, et al. Gynecologic Cancer InterGroup. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer 2011;21:763-70.
29. Vencken PM, Kriege M, Hoogwerf D, Beugelink S, van der Burg ME, Hooning MJ, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol 2011;22:1346-52.
30. Hyman DM, Zhou Q, Iasonos A, et al. Improved survival for BRCA2-associated serous ovarian cancer compared with bothBRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 2011 Dec 2 [Epub ahead of print].
31. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008-15.
32. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, et al.AOCS Study Group. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 2009;15:1417-27.
33. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13. (Pubitemid 36077915)
34. Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 2011;12:1169-74.
35. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 2011;71:4412-22.
36. Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, et al. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 2011;13:1069-80.
37. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-8.
38. van der Burg ME, Boere IA, BernsPM. Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra. Ann Oncol 2011;22 (suppl 8):viii33-9.
39. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 2011;108:3406-11.
40. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A 2011;108:7547-52.